Strides Acquires US FDA Approved Manufacturing Facility in the US

Bangalore, India ‐ Strides Pharma Science Limited (Strides) today announced that its step  down  subsidiary  Strides  Pharma  Inc.(SPI)  has  acquired  a  USFDA(FDA)  approved  manufacturing  facility  in  Florida, US from Micelle BioPharma, Inc.  Micelle’s facility is based in Riviera Beach, Florida and is one of the very few manufacturing facilities in the  US with a soft gel capsule(SGC) manufacturing suite for formulations with containment needs.  It is also the  only  FDA  approved  integrated  manufacturing‐packaging  SGC  facility  in  the  US.  The  site  has  undergone  several successful FDA inspections and has no outstanding FDA observations.     

Strategic Rationale  

 US business  for Strides has seen a significant  ramp up over  the last  few quarters driven by sustained business growth in base products and new product introductions through its own front-end.

 SGC is one of the important pivots in the Company’s growth. Strides is one of the global leaders in Rx  SGC with a vast portfolio of over 10 approved SGCs in US and other regulated markets and a pipeline of  15 SGC ANDAs filed/under filing for the US.

 The company has over 2 billion annual capacity of SGC at its flagship site in Bangalore. The Florida site  will augment this capacity and will offer an alternate site to support the Company’s growth plans. 

 In  the  future,  Company  plans  to  expand  additional  dosage  format  suites  for  select  large  volume  products at the Florida facility.

 This  site  will  also  mirror  the  capabilities  of  its  formulations  facility  at  Singapore  which  helps  the  company  to  tap  opportunities  under  various  federal  government  procurement  programs  including  procurements administered by the Department of Veterans Affairs (VA)

SPI has acquired  the manufacturing facility under an asset purchase agreement with Micelle Biopharma,  Inc.  for  a  consideration  of  US$  0.5  Million  and  will  invest  up  to  US$  10  Million  to  build  incremental  capabilities and add additional dosage formats. With the addition of the Florida site, Strides now has eight  formulation sites globally catering to the regulated and emerging markets. 



Badree Komandur 

Executive Director ‐ Finance  +91 80 6784 074

Investor Relations:  Kannan. N: +91 98450 54745  Vikesh Kumar: +91 80 6784 0827  Sandeep Baid: +91 80 6784 0791  Email: Strides Pharma Science Limited  (Formerly Strides Shasun Limited)  CIN: L24230MH1990PLC057062  Regd.  Office:  201,  ‘Devavrata’,  Sector  ‐  17,  Vashi,  Navi Mumbai ‐ 400 703  Corp.  Office:  Strides  House,  Bannerghatta  Road,  Bangalore – 560076 

PR Consultancy   Fortuna PR  K Srinivas Reddy: +91 90005 27213   K Priya: +91 95354 25418  

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Strides Pharma

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global  pharmaceutical  company  headquartered  in  Bangalore,  India.    The  Company  mainly  operates  in  the  regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service  donor‐funded  markets.  The  Company’s  global  manufacturing  sites  are  located  in  India‐  Bangalore  (two  sites),  Pondicherry,  and  Chennai,  Singapore,  Italy‐  Milan,  Kenya‐  Nairobi  and  United  States‐Florida.  The  Company  focusses on “difficult  to manufacture” products  that are  sold in over  100 countries.